Macrophages influence their environment and surrounding immune cells as
soon as stimulators affect them. Different sources of macrophages induce different reactions
in their neighboring immune cells,which result in non-uniform immunologic outcomes.
In this experimental research, we compare the behavior of peritoneal macrophages
to lipopolysaccharide (LPS) stimulation from BALB/cmice as an indicator of a type 2
immune response and from C57BL/6 mice as an indicator of a type 1 immune response.
Materials and Methods:
In this experimental study, peritoneal macrophages prepared
from thioglycolate stimulated BALB/c and C57BL/6 micewere treated with 1µg/ml LPS.
At different time points after LPS treatment, nitric oxide (NO), interferon gamma (IFN-λ),
interleukin 4 (IL-4),transforming growth factor β1(TGF-β1), interleukin 17 (IL-17), and interleukin
10(IL-10) production were measured in the supernatants of all macrophage cultures.
Indoleamine 2, 3 dioxygenase (IDO) and phagocytic activitywere analyzed in the
different experimental groups. The supernatant effects of LPS-treated macrophages on
splenocyte proliferation was assessed by the colorimetric method using a 3-(4,5-Dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reagent.
According to cytokine analysis, different mouse strains show different cytokine
patterns in response to LPS. C57BL/6 macrophages produced more IL-17, IL-10, and
IFN-λ, while BALB/c macrophages produced more TGF-β1 and IL-4. There was no significant
difference in IDO activity between strains (p≤0.05). BALB/c mice produced more
NO inthe first 24 hours after LPS treatment,but C57BL/6 produced more NO at 72 hours
post-LPS treatment. Macrophages from both strains hada suppressor effect on splenocyte
proliferation, but this effect was stronger in BALB/c mice.
The results show that macrophages from different genetic backgrounds respond
differently to the same stimulus in aspects of type, intensity, and time of response.
The consideration of these aspects will enableresearchers to use correct treatment programs
for immune-regulation or immunotherapy.